Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sun Pharmaceutical Industries has launched Kapspargo Sprinkle (metoprolol succinate) extended-release capsules in the US, for the treatment of hypertension (to lower blood pressure), angina pectoris (chest pain), and heart failure.
Image: A corporate office of Sun Pharma. Photo: courtesy of Sun Pharmaceutical Industries Ltd.
Subscribe to our email newsletter
Kapspargo Sprinkle, a U.S. Food and Drug Administration (FDA) approved, novel, patented formulation of metoprolol succinate, is the first and only extended-release sprinkle formulation of this beta1-selective adrenoreceptor blocking agent (beta-blocker). It is covered by United States Patent numbers 9,504,655 and 9,700,530, expiring Jul 09, 2035.
Kapspargo Sprinkle pellets can be sprinkled over soft food (such as applesauce, yogurt or pudding) or administered via a nasogastric tube, and are designed to facilitate long-term, once-daily administration, particularly for patients who have difficulty swallowing.
Sun Pharma North America CEO Abhay Gandhi said: “Roughly 40% of patients requiring long-term care have difficulty swallowing, a problem that may result in patient non-adherence to medications as well as medication errors.
“Kapspargo Sprinkle capsules may make it easier for patients to take their antihypertensive medication. This innovative product is the latest example of Sun Pharma’s use of advanced technology to create novel formulations of proven medications.”
Source: Company Press Release
